EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration

Seung Wan Noh, Han Sol Ryu, Yong-Ho Kim, Byung-Chul Oh

Endocrinology and Metabolism · 31.12.2025 · 40 (6) · 851-865

DOI: 10.3803/enm.2025.2786 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism, erschienen am 31.12.2025. Verfasst von Seung Wan Noh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Science and Technology, Gachon Advanced Institute for Health Science and Technology, Gachon University, Incheon, Korea. Hauptthemen laut MEDLINE: Fatty Liver, Metabolic Diseases, Sodium-Glucose Transporter 2 Inhibitors, Liver. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT, Gachon University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as paradigm-shifting therapeutics that extend beyond glycemic regulation, to conferring profound hepatometabolic benefits. This review delineates the multifaceted mechanisms underlying metabolic dysfunction-associated steatotic liver disease (MASLD), with an emphasis on systemic metabolic remodeling, mitochondrial protection, and intracellular calcium restoration. By promoting glucosuria-induced energy depletion, SGLT2 inhibition alleviates insulin resistance, suppresses hepatic lipogenesis, and activates adenosine monophosphate-activated protein kinase (AMPK)–sirtuin 1 (SIRT1)–peroxisome proliferator-activated receptor γ (PPARγ) coactivator-1α pathways that reprogram hepatocellular metabolism toward achieving lipid oxidation and autophagy. Mechanistically, SGLT2 inhibitors restore intracellular Ca2+ homeostasis via sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) activation, mitigating endoplasmic reticulum (ER) stress and normalizing Ca2+–phosphoinositide (PIP)–protein kinase B (AKT) signaling, collectively reinforcing insulin responsiveness and ER-mitochondrial crosstalk. Clinically, these effects translate into consistently reducing hepatic fat, aminotransferases, and fibrosis markers in both diabetic and nondiabetic patients with MASLD. Furthermore, SGLT2 inhibitors uniquely integrate renal energy regulation with hepatic resilience through the Ca2+–PIP–SERCA axis, positioning them as prototype systemic modulators of metabolic homeostasis. Future translational efforts should refine patient stratification using metabolomic and Ca2+-imaging biomarkers to delineate therapeutic responders and advance next-generation SGLT2 analogs targeting Ca2+-dependent metabolic signaling. Collectively, SGLT2 inhibitors represent a new metabolic therapeutic class that unify glucose, lipid, and Ca2+ regulation to restore hepatocellular functions in metabolic liver diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty LiverMetabolic DiseasesSodium-Glucose Transporter 2 InhibitorsLiverGlucoseHumansInsulin ResistanceLipogenesisEndoplasmic ReticulumSignal TransductionAnimals

Stichwörter der Autor:innen

Endoplasmic reticulum stressInsulin resistanceIntracellular calcium homeostasisLiver diseasesSarcoplasmic reticulum calcium-transporting ATPasesSodium-glucose transporter 2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucose

Autor:innen und Institutionen

  • Department of Health Science and Technology, Gachon Advanced Institute for Health Science and Technology, Gachon University, Incheon, Korea.
  • Department of Physiology, Lee Gil Ya Cancer and Diabetes Institute, Gachon University College of Medicine, Incheon, Korea.

Förderung

  • National Research Foundation of Korea
  • Ministry of Science and ICT
  • Gachon University

Zitieren

APA

Noh, S. W., Ryu, H. S., Kim, Y. H., & Oh, B. C. (2025). SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration. Endocrinology and Metabolism, 40(6), 851-865. https://doi.org/10.3803/enm.2025.2786

Vancouver

Noh SW, Ryu HS, Kim YH, Oh BC. SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration. Endocrinology and Metabolism. 2025;40(6):851-865. doi:10.3803/enm.2025.2786

BibTeX
@article{Noh2025,
  author = {Noh, Seung Wan and Ryu, Han Sol and Kim, Yong-Ho and Oh, Byung-Chul},
  title = {SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration},
  journal = {Endocrinology and Metabolism},
  year = {2025},
  volume = {40},
  number = {6},
  pages = {851--865},
  doi = {10.3803/enm.2025.2786}
}
Kostenlos starten →